Aliases & Classifications for Endometriosis

MalaCards integrated aliases for Endometriosis:

Name: Endometriosis 12 73 36 29 54 6 42 44 15 62 17 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:289
KEGG 36 H01639
ICD9CM 34 617
MeSH 44 D004715
NCIt 50 C3014
SNOMED-CT 67 11871002
ICD10 32 N80 N80.9
UMLS 70 C0014175

Summaries for Endometriosis

MedlinePlus : 42 What is endometriosis? The uterus, or womb, is the place where a baby grows when a woman is pregnant. It is lined with tissue (endometrium). Endometriosis is a disease in which tissue that is similar to the lining of the uterus grows in other places in your body. These patches of tissue are called "implants," "nodules," or "lesions." They are most often found On or under the ovaries On the fallopian tubes, which carry egg cells from the ovaries to the uterus Behind the uterus On the tissues that hold the uterus in place On the bowels or bladder In rare cases, the tissue may grow on your lungs or in other parts of your body. What causes endometriosis? The cause of endometriosis is unknown. Who is at risk for endometriosis? Endometriosis is most commonly diagnosed in women in their 30s and 40s. But it can affect any female who menstruates. Certain factors can raise or lower your risk of getting it. You are at higher risk if You have a mother, sister, or daughter with endometriosis Your period started before age 11 Your monthly cycles are short (less than 27 days) Your menstrual cycles are heavy and last more than 7 days You have a lower risk if You have been pregnant before Your periods started late in adolescence You regularly exercise more than 4 hours a week You have a low amount of body fat What are the symptoms of endometriosis? The main symptoms of endometriosis are Pelvic pain, which affects about 75 percent of women with endometriosis. It often happens during your period. Infertility, which affects up to half of all women with endometriosis Other possible symptoms include Painful menstrual cramps, which may get worse over time Pain during or after sex Pain in the intestine or lower abdomen Pain with bowel movements or urination, usually during your period Heavy periods Spotting or bleeding between periods Digestive or gastrointestinal symptoms Fatigue or lack of energy How is endometriosis diagnosed? Surgery is the only way to know for sure that you have endometriosis. First, however, your health care provider will ask about your symptoms and medical history. You will have a pelvic exam and may have some imaging tests. The surgery to diagnose endometriosis is a laparoscopy. This is a type of surgery that uses a laparoscope, a thin tube with a camera and light. The surgeon inserts the laparoscope through a small cut in the skin. Your provider can make a diagnosis based on how the patches of endometriosis look. He or she may also do a biopsy to get a tissue sample. What are the treatments for endometriosis? There is no cure for endometriosis, but there are treatments for the symptoms. Your health care provider will work with you to decide which treatments would be best for you. Treatments for endometriosis pain include Pain relievers, including nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen and a prescription medicine specifically for endometriosis. Providers may sometimes prescribe opioids for severe pain. Hormone therapy, including birth control pills, progestin therapy, and gonadotropin-releasing hormone (GnRH) agonists. GnRH agonists cause a temporary menopause, but also help control the growth of endometriosis. Surgical treatments for severe pain, including procedures to remove the endometriosis patches or cut some nerves in the pelvis. The surgery may be a laparoscopy or major surgery. The pain may come back within a few years after surgery. If the pain is very severe, a hysterectomy may be an option. This is a surgery to remove the uterus. Sometimes providers also remove the ovaries and fallopian tubes as part of a hysterectomy. Treatments for infertility caused by endometriosis include Laparoscopy to remove the endometriosis patches In vitro fertilization NIH: National Institute of Child Health and Human Development

MalaCards based summary : Endometriosis is related to ovarian epithelial cancer and endometrial cancer, and has symptoms including pelvic pain and pain and other symptoms associated with female genital organs. An important gene associated with Endometriosis is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Dienogest and Drospirenone have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and endothelial.

Disease Ontology : 12 A female reproductive system disease characterized by the growth of endometrial tissue outside the uterine body.

KEGG : 36 Endometriosis is defined as the growth of the endometrial glands and stroma at extra-uterine sites, which are most commonly implanted over and under visceral and peritoneal surfaces within the female pelvis but which can also be found in the connective tissue in the pelvis areas and, more rarely, in any anatomic district. It is a major cause of infertility, dysmenorrhea, dyspareunia, and chronic pelvic pain, mediated by marked pelvic inflammation. While retrograde menstruation is the most widely accepted cause, its pathogenesis and natural course are not fully understood. Endometriosis is known to be a estrogen-dependent disease, manifests during reproductive years.

PubMed Health : 62 About endometriosis: Endometriosis is one of the most common medical conditions affecting the abdomen (lower belly) in women. In endometriosis, the kind of tissue that normally lines the inside of the womb (endometrial tissue) also grows outside of it. The medical term for endometrial tissue that has grown outside of the womb is “endometrial implants.” Some women have them without knowing it. But other women experience endometriosis as a chronic disease that causes severe pain and fertility problems. It often takes years for endometriosis to be diagnosed as the cause of these problems. Until the diagnosis is made, many women try to cope with their pain somehow. They believe that the pain – even really bad pain – is a normal part of their menstrual period. There is currently no cure for endometriosis. But there are many things that can be done to relieve the symptoms. If treatment is adapted to suit women’s personal circumstances and the severity of their endometriosis, many can cope quite well with the disease. Like with other chronic conditions, it's important to get to know your own body and how it reacts, in order to find ways to manage the symptoms. Getting hold of good information and consulting experienced, supportive doctors can help.

Wikipedia : 73 Endometriosis is a full body condition in which cells similar to those in the endometrium, the layer of... more...

Related Diseases for Endometriosis

Diseases in the Endometriosis family:

Endometriosis 1

Diseases related to Endometriosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 789)
# Related Disease Score Top Affiliating Genes
1 ovarian epithelial cancer 30.9 MIR126 MIR125A MIR100 H19
2 endometrial cancer 30.6 MIR200B MIR200A MIR145 MIR142 MIR141 MIR126
3 in situ carcinoma 30.5 MIR143 MIR142 MIR126
4 uterine anomalies 30.4 MIR99A MIR34C MIR29C MIR200B MIR200A MIR145
5 mayer-rokitansky-kuster-hauser syndrome 30.3 WNT4 H19
6 ovarian disease 30.0 MIR223 MIR200B MIR200A MIR145 MIR143 MIR141
7 cervical cancer 29.9 MIR200A MIR145 MIR143 MIR126 MIR125A H19
8 lung cancer susceptibility 3 29.8 MIR200B MIR200A MIR145 MIR126 H19
9 rectum cancer 29.7 MIR99A MIR424 MIR20A MIR200A MIR145 MIR143
10 renal hypertension 29.7 MIR200B MIR200A MIR141
11 disease by infectious agent 29.6 MIR223 MIR142 MIR126 MIR125A
12 intestinal benign neoplasm 29.6 MIR20A MIR145 MIR143 MIR142
13 multiple sclerosis 29.5 MIR223 MIR20A MIR145 MIR142 MIR125A
14 peripheral nervous system disease 29.5 MIR424 MIR142 MIR126 MIR125A
15 leukemia, acute lymphoblastic 29.4 MIR424 MIR223 MIR142 MIR126 MIR125A CDKN2B-AS1
16 breast disease 29.4 MIR20A MIR200B MIR200A MIR145 MIR143 MIR142
17 lymphoma, non-hodgkin, familial 29.3 MIR424 MIR20A MIR200B MIR143 MIR142 MIR126
18 kidney cancer 29.2 MIR424 MIR29C MIR20A MIR200B MIR141 MIR126
19 melanoma 29.2 MIR34C MIR200B MIR200A MIR141 MIR100 H19
20 lipoprotein quantitative trait locus 29.2 MIR223 MIR145 MIR143 MIR142 MIR126 H19
21 ovarian cancer 29.1 MIR99A MIR424 MIR34C MIR29C MIR223 MIR200B
22 arteries, anomalies of 28.9 MIR29C MIR223 MIR145 MIR143 MIR142 MIR141
23 bladder cancer 28.8 MIR99A MIR29C MIR223 MIR200A MIR145 MIR143
24 body mass index quantitative trait locus 11 28.8 MIR223 MIR143 MIR142 MIR126 MIR125A MIR100
25 intestinal disease 28.5 MIR99A MIR424 MIR29C MIR223 MIR20A MIR200B
26 pharynx cancer 28.5 MIR99A MIR34C MIR29C MIR223 MIR145 MIR143
27 bladder disease 28.4 MIR99A MIR424 MIR34C MIR29C MIR200A MIR145
28 renal cell carcinoma, nonpapillary 28.3 MIR99A MIR424 MIR29C MIR200A MIR145 MIR143
29 gastrointestinal system disease 27.9 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A
30 reproductive system disease 27.6 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A
31 urinary system disease 27.6 MIR99A MIR424 MIR29C MIR223 MIR20A MIR200B
32 colorectal cancer 27.3 WNT4 MIR99A MIR424 MIR34C MIR29C MIR223
33 endometriosis of ovary 11.7
34 adenomyosis 11.5
35 extrapelvic endometriosis 11.3
36 catamenial pneumothorax 11.3
37 fallopian tube endometriosis 11.3
38 cervix endometriosis 11.3
39 endometriosis 1 11.2
40 infertility 11.2
41 adenosarcoma 11.1
42 endometriosis of pelvic peritoneum 11.1
43 endometriosis of intestine 11.1
44 endometriosis of rectovaginal septum and vagina 11.1
45 chronic pain 11.1
46 endometriosis in scar of skin 11.0
47 benign multicystic peritoneal mesothelioma 10.9
48 ovarian cyst 10.7
49 pneumothorax 10.7
50 constipation 10.7

Comorbidity relations with Endometriosis via Phenotypic Disease Network (PDN):


Myofibroma

Graphical network of the top 20 diseases related to Endometriosis:



Diseases related to Endometriosis

Symptoms & Phenotypes for Endometriosis

UMLS symptoms related to Endometriosis:


pelvic pain; pain and other symptoms associated with female genital organs

Drugs & Therapeutics for Endometriosis

PubMed Health treatment related to Endometriosis: 62

There is currently no “cure” for endometriosis – in other words, there are no treatments that can fight what is causing it. But various treatments can help relieve the symptoms, temporarily or permanently. The medication options include painkillers, hormonal contraception and stronger hormone therapy . Painkillers only relieve the symptoms, whereas hormone-based treatments slow down the growth of endometrial implants . Surgery is also an option. The aim of surgery for endometriosis is usually to remove as many endometrial implants as possible. Sometimes surgery is even necessary – for instance, if endometriosis is affecting bowel or bladder function.

Drugs for Endometriosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 269)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dienogest Approved Phase 4 65928-58-7
2
Drospirenone Approved Phase 4 67392-87-4 68873
3
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
4
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
5
Danazol Approved Phase 4 17230-88-5 28417
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
8
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
9
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
10
Sage Approved Phase 4
11
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
12
tannic acid Approved Phase 4 1401-55-4
13
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
14
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Norethindrone Approved Phase 4 68-22-4 6230
19
Metronidazole Approved Phase 4 443-48-1 4173
20
Ferrous fumarate Approved Phase 4 141-01-5
21
Tibolone Approved, Investigational Phase 4 5630-53-5
22
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
23
Calcium carbonate Approved, Investigational Phase 4 471-34-1
24
Norgestrel Approved Phase 4 6533-00-2 13109
25
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
28
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
30
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
31
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
32
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
33
Gallopamil Investigational Phase 4 16662-47-8
34
Resveratrol Investigational Phase 4 501-36-0 445154
35
Gestodene Investigational Phase 4 60282-87-3 3033968
36 Contraceptive Agents, Male Phase 4
37 Drospirenone and ethinyl estradiol combination Phase 4
38 Adjuvants, Immunologic Phase 4
39 Viscosupplements Phase 4
40 Ulipristal acetate Phase 4 126784-99-4
41 Platelet Aggregation Inhibitors Phase 4
42 Neuromuscular Blocking Agents Phase 4
43 Neuromuscular Nondepolarizing Agents Phase 4
44 Dopamine agonists Phase 4
45 Somatomedin B Phase 4
46
Medroxyprogesterone Phase 4 520-85-4 10631
47 Omega 3 Fatty Acid Phase 4
48 Ergocalciferols Phase 4
49 Vitamin D2 Phase 4
50 Contraceptives, Oral Phase 4

Interventional clinical trials:

(show top 50) (show all 504)
# Name Status NCT ID Phase Drugs
1 Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest Unknown status NCT02575248 Phase 4 Dienogest 2mg;Clomiphene citrate 5 mg
2 A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery Unknown status NCT02385448 Phase 4 Dienogest;Microgynon
3 A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain Unknown status NCT02031523 Phase 4 Sanjie analgesic capsule;placebo
4 Randomised, Controlled Clinical Study With Patients With Endometriosis and the Desire to Have Children - Comparison Between Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesionbarrier Unknown status NCT02165917 Phase 4
5 Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial. Unknown status NCT00844012 Phase 4 Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy);Cyclic OC (clormadinone acetate plus ethinil-estradiol)
6 A Randomized Study Comparing Goserelin or Expectant Management Following Laparoscopic Surgery for Advanced Endometriosis Unknown status NCT00654524 Phase 4 gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
7 Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis Unknown status NCT02237131 Phase 4 Oral contraceptives cyclic;Oral contraceptives continuous
8 Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain Unknown status NCT02213081 Phase 4 Ulipristal
9 Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving, Using Indocyanine Green Injection. Feasibility Study Unknown status NCT03080558 Phase 4 Indocyanine green
10 Trans-vaginal Aspiration With or Without Injection of Surgicel for Treatment of Small Ovarian Endometrioma Before ICSI Cycles. A Randomized Controlled Trial Unknown status NCT03784404 Phase 4 Intracytoplasmic sperm injection
11 Effects of Dienogest and Dienogest Plus Estradiol Valerate on Ovarian Reserve and Endometrioma Size Unknown status NCT03789123 Phase 4 Estradiol valerate/dienogest
12 A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women Completed NCT00735852 Phase 4 Decapeptyl SR 11.25mg
13 IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates. Completed NCT01682642 Phase 4 Zoladex
14 Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial Completed NCT02158845 Phase 4 LNG-IUS: levonorgestrel intrauterine system;GnRHa: leuprolide
15 Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF Completed NCT01779232 Phase 4 Danazol;placebo
16 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
17 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
18 The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial Completed NCT02475564 Phase 4 Placebo;Resveratrol
19 Do Endometrial Implantation Markers Predict in Vitro Fertilization-embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension? Completed NCT00621179 Phase 4 Leuprolide acetate in depot suspension
20 Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis Completed NCT02480647 Phase 4 Levonorgestrel;Etonogestrel
21 Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis Completed NCT02427386 Phase 4 dynamized estrogen;placebo
22 A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment Completed NCT01581359 Phase 4 Triptorelin acetate
23 Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. Completed NCT01056042 Phase 4 intramuscular depot medroxyprogesterone acetate;ethinyl estradiol 30 micrograms, gestodene 75 micrograms
24 SAGE: Supplementation in Adolescent Girls With Endometriosis Completed NCT02387931 Phase 4
25 Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis Completed NCT00286351 Phase 4 Combined treatment with Arimidex and Zoladex before IVF
26 Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide). Completed NCT01769781 Phase 4 anastrazole;GnRH analog alone
27 Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients Completed NCT02534688 Phase 4 LNG-IUS;DMPA
28 Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions. Completed NCT00625950 Phase 4
29 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
30 The Efficacy and Safety of Xuefu Zhuyu Capsule in Treating "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome): a Randomized, Double-blind, Placebo-controlled, Adaptive Enrichment, Multicenter Controlled Trial Recruiting NCT04218487 Phase 4 Xuefu-Zhuyu Capsule;placebo
31 The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery: A Prospective, Randomized, Placebo-Controlled Trial Recruiting NCT04554693 Phase 4 Metronidazole Oral;Placebo
32 Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
33 Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study Not yet recruiting NCT02393482 Phase 4 Estroprogestinic therapy (Etinil-estradiol/levonorgestre);Gonadotropin-releasing hormone agonist (Leuprorelin acetate);Add back therapy 1 (tibolone);Add back therapy 2 (calcium carbonate/colecalciferol)
34 A Single Centre Open-label Randomised Controlled Trial of Long Term Pituitary Down-regulation Before in Vitro Fertilisation for Women With Endometriosis: a Pilot Study Terminated NCT01757249 Phase 4 Combined Oral Contraceptive Pill (Microgynon 30)
35 Peritoneal Cavity Conditioning During Laparoscopic Surgery Decreases Postoperative Pain, Inflammatory Reaction and Postoperative Adhesions Terminated NCT01344486 Phase 4
36 The Role of the Subcutaneous Progesterone in Luteal Phase Supplementation in Patients With Endometriosis Unknown status NCT02793908 Phase 3 Pleyris;Crinone8
37 Study Comparing Laparoscopy Versus Laparotomy in the Treatment of Colorectal Endometriosis Unknown status NCT00939861 Phase 3
38 Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial Unknown status NCT01125488 Phase 3 GnRH agonist (triptorelin)
39 Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis: A Randomized Controlled Trial Unknown status NCT02470169 Phase 3 Merional;Choriomon
40 Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study Unknown status NCT02437175 Phase 3
41 Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) Unknown status NCT00458458 Phase 3 Norethindrone Acetate (NA);GnRH Agonist (Lupron Depot)
42 Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery Unknown status NCT01973816 Phase 3 Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;;Cyproterone acetate 50 mg; estradiol 0.5% percutaneous;Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral
43 The in Vitro Fertilisation - Lipiodol Uterine Bathing Effect Study Unknown status NCT00894946 Phase 3
44 Combined Laparoscopic Surgery and Pentoxifylline Therapy for Treatment of Endometriosis-Associated Infertility: A Preliminary Study Completed NCT00632697 Phase 3 pentoxifylline;placebo
45 Oral Contraceptives Versus Depot-Leuprolide Taken After Surgery for Endometriosis-Associated Pelvic Pain Completed NCT00229996 Phase 3 Oral Contraceptive;Depot-Leuprolide/Norethindrone
46 Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence Completed NCT01712763 Phase 3 degarelix;goserelin
47 A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (β-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis Completed NCT01697111 Phase 3 EE20/DRSP(BAY86-5300);Placebo;Dienogest
48 Phase3, Open-Label, Long-Term, NSAID-Add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea Associated With Endometriosis. Completed NCT00902746 Phase 3 NPC-01
49 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain Completed NCT01620528 Phase 3 elagolix
50 Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis Completed NCT02271958 Phase 2, Phase 3 Mifepristone;PLACEBO

Search NIH Clinical Center for Endometriosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


17-alpha-Hydroxyprogesterone
Danazol
Desogestrel
Ethynodiol Diacetate
Goserelin Acetate
hydroxyprogesterone caproate (USP)
Leuprolide
Leuprolide Acetate
Nafarelin
Nafarelin Acetate
Norethindrone
norethindrone acetate

Cochrane evidence based reviews: endometriosis

Genetic Tests for Endometriosis

Genetic tests related to Endometriosis:

# Genetic test Affiliating Genes
1 Endometriosis 29

Anatomical Context for Endometriosis

MalaCards organs/tissues related to Endometriosis:

40
Uterus, Ovary, Endothelial, Colon, Appendix, Cervix, Bone

Publications for Endometriosis

Articles related to Endometriosis:

(show top 50) (show all 24008)
# Title Authors PMID Year
1
The efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis: A protocol for systematic review and meta-analysis. 61 42
33725984 2021
2
Does endometriosis increase susceptibility to COVID-19 infections? A case-control study in women of reproductive age. 61 42
33752656 2021
3
Knockdown of lncRNA H19 suppresses endometriosis in vivo. 42 61
33656053 2021
4
MicroRNA-regulated pathways associated with endometriosis. 47 61
19074548 2009
5
Letrozole and norethisterone acetate in colorectal endometriosis. 61 54
20227163 2010
6
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 54 61
19342032 2010
7
Matrix metalloproteinase messenger RNA expression in human endometriosis grafts cultured on a chicken chorioallantoic membrane. 61 54
19345347 2010
8
Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. 61 54
19324337 2010
9
Endometriotic epithelial cells induce MMPs expression in endometrial stromal cells via an NFkappaB-dependent pathway. 54 61
19903119 2010
10
Interleukin-4 induces expression of eotaxin in endometriotic stromal cells. 54 61
19338989 2010
11
Steroidogenic factor-1 expression in ovarian endometriosis. 61 54
19875956 2010
12
The roles of thioredoxin and thioredoxin-binding protein-2 in endometriosis. 61 54
20172870 2010
13
[Treatment of endometriosis by aromatase inhibitors: efficacy and side effects]. 54 61
20430665 2010
14
[Aromatase and endometriosis: myth or reality]. 54 61
20430669 2010
15
Immunohistochemical detection of steroid receptor cofactors in ovarian endometriosis: involvement of down-regulated SRC-1 expression in the limited growth activity of the endometriotic epithelium. 54 61
20155281 2010
16
Estrogen and progesterone receptors in smooth muscle component of deep infiltrating endometriosis. 54 61
19217090 2010
17
Proteomic analysis of endometrium from fertile and infertile patients suggests a role for apolipoprotein A-I in embryo implantation failure and endometriosis. 54 61
20008415 2010
18
Effect of human seminal fluid on the growth of endometrial cells of women with endometriosis. 54 61
20092935 2010
19
Expression of macrophage migration inhibitory factor in human endometriosis: relation to disease stage, menstrual cycle and infertility. 61 54
20492386 2010
20
[Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in human and nude mouse ectopic endometrium and the effect of estrogen and progestin on their expression]. 61 54
20423842 2010
21
17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. 61 54
19932734 2010
22
Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis. 54 61
20007614 2010
23
Regulation of monocyte chemotactic protein-1 expression in human endometrial endothelial cells by sex steroids: a potential mechanism for leukocyte recruitment in endometriosis. 54 61
19933497 2010
24
Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. 54 61
20007161 2010
25
Effect of vascular endothelial growth factor and interleukin-1beta on apoptosis in endometrial cell cultures from patients with endometriosis and controls. 54 61
20137818 2010
26
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. 54 61
20074813 2010
27
Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis. 61 54
20023295 2010
28
Influence of peritoneal fluid on the expression of angiogenic and proteolytic factors in cultures of endometrial cells from women with endometriosis. 61 54
19945964 2010
29
Association of interleukin 1beta gene (+3953) polymorphism and severity of endometriosis in Turkish women. 54 61
19757173 2010
30
Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. 61 54
20085636 2010
31
Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis. 61 54
20068324 2010
32
Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. 61 54
20104427 2010
33
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. 54 61
20108182 2010
34
Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions. 61 54
20104430 2010
35
Lipopolysaccharide promoted proliferation and invasion of endometriotic stromal cells via induction of cyclooxygenase-2 expression. 61 54
19647233 2010
36
Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software, and cytokine analysis in women with and without endometriosis. 61 54
19892605 2010
37
Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. 54 61
19898423 2010
38
Haptoglobin expression in endometrioid adenocarcinoma of the uterus. 61 54
19801537 2010
39
Cyclooxygenase-2 expression, Ki-67 labeling index, and perifocal neovascularization in endometriotic lesions. 54 61
19917472 2009
40
HOXA-10 expression in the mid-secretory endometrium of infertile patients with either endometriosis, uterine fibromas or unexplained infertility. 61 54
19736237 2009
41
Elevated ghrelin levels in the peritoneal fluid of patients with endometriosis: associations with vascular endothelial growth factor (VEGF) and inflammatory cytokines. 61 54
18976754 2009
42
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. 54 61
19726448 2009
43
Fenofibrate causes regression of endometriotic implants: a rat model. 61 54
19580963 2009
44
Electrodermal measures of Jing-Well points and their clinical relevance in endometriosis-related chronic pelvic pain. 54 61
19958132 2009
45
Effect of Yikun Neiyi Wan on the expression of aromatase P450, COX-2, and ER related receptor in endometrial cells in vitro from patients with endometriosis. 61 54
20112494 2009
46
Hepatocyte nuclear factor-1beta(HNF-1beta) in human urogenital organs: its expression and role in embryogenesis and tumorigenesis. 61 54
19760597 2009
47
Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. 61 54
20512287 2009
48
CYP17 and CYP19 gene polymorphisms in women affected with endometriosis. 54 61
18930188 2009
49
Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. 54 61
19661125 2009
50
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis. 54 61
19903048 2009

Variations for Endometriosis

ClinVar genetic disease variations for Endometriosis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FAM163A t(1;5)(q25;q12) Translocation Uncertain significance 810664 GRCh37: 1:179785309-179785316
GRCh38:

Expression for Endometriosis

LifeMap Discovery
Genes differentially expressed in tissues of Endometriosis patients vs. healthy controls: 35 (show top 50) (show all 83)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PTGIS prostaglandin I2 synthase Uterus + 5.41 0.000
2 MYH11 myosin heavy chain 11 Uterus + 4.87 0.001
3 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide Uterus + 4.81 0.000
4 CNN1 calponin 1 Uterus + 4.71 0.000
5 TAGLN transgelin Uterus + 4.63 0.000
6 PAEP progestagen associated endometrial protein Uterus + 4.63 0.013
7 PRELP proline and arginine rich end leucine rich repeat protein Uterus + 4.59 0.000
8 C7 complement C7 Uterus + 4.54 0.003
9 ACTG2 actin gamma 2, smooth muscle Uterus + 4.48 0.003
10 TCF21 transcription factor 21 Uterus + 4.45 0.000
11 HPGD 15-hydroxyprostaglandin dehydrogenase Uterus - 4.42 0.001
12 CCN5 cellular communication network factor 5 Uterus + 4.11 0.001
13 AQP1 aquaporin 1 (Colton blood group) Uterus + 4.10 0.000
14 EHF ETS homologous factor Uterus - 4.10 0.000
15 FOS Fos proto-oncogene, AP-1 transcription factor subunit Uterus + 4.09 0.000
16 FOSB FosB proto-oncogene, AP-1 transcription factor subunit Uterus + 4.07 0.000
17 SLC3A1 solute carrier family 3 member 1 Uterus - 4.05 0.010
18 LMNB1 lamin B1 Uterus - 4.05 0.000
19 SLC26A4 solute carrier family 26 member 4 Uterus - 3.99 0.000
20 DPT dermatopontin Uterus + 3.98 0.000
21 DES desmin Uterus + 3.97 0.001
22 KCNMB1 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Uterus + 3.96 0.001
23 GATA6 GATA binding protein 6 Uterus + 3.89 0.004
24 FZD7 frizzled class receptor 7 Uterus + 3.89 0.000
25 LEFTY2 left-right determination factor 2 Uterus + 3.88 0.001
26 SLC26A4 solute carrier family 26 member 4 Uterus - 3.87 0.001
27 HPGD 15-hydroxyprostaglandin dehydrogenase Uterus - 3.86 0.001
28 ACKR1 atypical chemokine receptor 1 (Duffy blood group) Uterus + 3.84 0.001
29 EFHC2 EF-hand domain containing 2 Uterus - 3.75 0.000
30 PDLIM3 PDZ and LIM domain 3 Uterus + 3.72 0.001
31 GPC3 glypican 3 Uterus + 3.71 0.003
32 IL20RA interleukin 20 receptor subunit alpha Uterus - 3.70 0.000
33 MYL9 myosin light chain 9 Uterus + 3.70 0.001
34 VNN1 vanin 1 Uterus - 3.69 0.008
35 CTSZ cathepsin Z Uterus - 3.68 0.000
36 EHF ETS homologous factor Uterus - 3.67 0.000
37 LMNB1 lamin B1 Uterus - 3.61 0.000
38 CLU clusterin Uterus + 3.58 0.002
39 ACTA2 actin alpha 2, smooth muscle Uterus + 3.57 0.000
40 TCEAL2 transcription elongation factor A like 2 Uterus + 3.53 0.001
41 LMOD1 leiomodin 1 Uterus + 3.52 0.003
42 LMO3 LIM domain only 3 Uterus + 3.51 0.002
43 TPD52 tumor protein D52 Uterus - 3.50 0.000
44 SYNPO synaptopodin Uterus + 3.48 0.001
45 KLF2 Kruppel like factor 2 Uterus + 3.44 0.000
46 AOC3 amine oxidase copper containing 3 Uterus + 3.44 0.003
47 KCNK3 potassium two pore domain channel subfamily K member 3 Uterus + 3.44 0.007
48 ZBBX zinc finger B-box domain containing Uterus - 3.43 0.001
49 FMO1 flavin containing dimethylaniline monoxygenase 1 Uterus + 3.43 0.000
50 ZBBX zinc finger B-box domain containing Uterus - 3.42 0.002
Search GEO for disease gene expression data for Endometriosis.

Pathways for Endometriosis

Pathways related to Endometriosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR99A MIR34C MIR29C MIR223 MIR20A MIR200B
2 11.03 MIR34C MIR145 MIR100
3 10.77 MIR200B MIR200A MIR141

GO Terms for Endometriosis

Cellular components related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 WNT4 MIR99B MIR99A MIR424 MIR29C MIR223
2 extracellular vesicle GO:1903561 9.43 MIR99A MIR29C MIR20A MIR126 MIR125A MIR100

Biological processes related to Endometriosis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.83 MIR99B MIR20A MIR143 MIR126
2 negative regulation of cell migration GO:0030336 9.81 WNT4 MIR29C MIR145 MIR126
3 negative regulation of gene expression GO:0010629 9.8 WNT4 MIR29C MIR20A MIR200B MIR125A CDKN2B-AS1
4 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.73 MIR424 MIR29C MIR20A
5 positive regulation of blood vessel endothelial cell migration GO:0043536 9.72 MIR200A MIR143 MIR126
6 negative regulation of protein kinase B signaling GO:0051898 9.67 MIR34C MIR29C MIR20A MIR145
7 miRNA mediated inhibition of translation GO:0035278 9.65 MIR29C MIR20A MIR200B MIR145 MIR100
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.63 MIR424 MIR29C MIR126
9 negative regulation of inflammatory response GO:0050728 9.63 MIR223 MIR20A MIR145 MIR142 MIR141 MIR126
10 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.62 WNT4 MIR424
11 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR424 MIR223
12 regulation of smooth muscle contraction GO:0006940 9.61 MIR145 MIR143
13 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.6 MIR99A MIR125A
14 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.59 MIR34C MIR20A
15 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR141 MIR125A
16 angiotensin-activated signaling pathway GO:0038166 9.58 MIR145 MIR143
17 negative regulation of STAT cascade GO:1904893 9.57 MIR99A MIR125A
18 gene silencing by miRNA GO:0035195 9.55 MIR99B MIR99A MIR424 MIR34C MIR29C MIR223
19 aorta smooth muscle tissue morphogenesis GO:0060414 9.54 MIR145 MIR143
20 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.49 MIR20A MIR143
21 regulation of phenotypic switching GO:1900239 9.48 MIR145 MIR143
22 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR145 MIR143
23 negative regulation of angiogenesis GO:0016525 9.43 MIR424 MIR29C MIR200B MIR145 MIR143 MIR125A
24 negative regulation of interleukin-16 production GO:0032699 9.4 MIR145 MIR125A

Molecular functions related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 MIR424 MIR29C MIR20A MIR200B MIR145 MIR143
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR99A MIR424 MIR29C MIR223 MIR20A MIR200B
3 RNA polymerase II complex binding GO:0000993 9.46 MIR20A MIR145 MIR126 MIR125A

Sources for Endometriosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....